DK502189A - Forbedringer ved eller vedroerende antistoffer - Google Patents

Forbedringer ved eller vedroerende antistoffer

Info

Publication number
DK502189A
DK502189A DK502189A DK502189A DK502189A DK 502189 A DK502189 A DK 502189A DK 502189 A DK502189 A DK 502189A DK 502189 A DK502189 A DK 502189A DK 502189 A DK502189 A DK 502189A
Authority
DK
Denmark
Prior art keywords
framework regions
antibodies
relating
origin
antibody
Prior art date
Application number
DK502189A
Other languages
English (en)
Other versions
DK174854B1 (da
DK502189D0 (da
Inventor
Herman Waldmann
Michael Ronald Clark
Gregory Paul Winter
Lutz Riechmann
Original Assignee
Medical Res Council
Herman Waldmann
Michael Ronald Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888803228A external-priority patent/GB8803228D0/en
Priority claimed from GB888804464A external-priority patent/GB8804464D0/en
Application filed by Medical Res Council, Herman Waldmann, Michael Ronald Clark filed Critical Medical Res Council
Publication of DK502189D0 publication Critical patent/DK502189D0/da
Publication of DK502189A publication Critical patent/DK502189A/da
Application granted granted Critical
Publication of DK174854B1 publication Critical patent/DK174854B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK198905021A 1988-02-12 1989-10-10 Antistoffer og fragmenter af antistoffer, præparater omfattende disse, anvendelse af disse til fremstilling af lægemidler samt cellelinier, der udtrykker disse DK174854B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB888803228A GB8803228D0 (en) 1988-02-12 1988-02-12 Improvements in/relating to antibodies
GB8803228 1988-02-12
GB8804464 1988-02-25
GB888804464A GB8804464D0 (en) 1988-02-25 1988-02-25 Improvements in/relating to antibodies
GB8900113 1989-01-04
PCT/GB1989/000113 WO1989007452A1 (en) 1988-02-12 1989-02-10 Improvements in or relating to antibodies

Publications (3)

Publication Number Publication Date
DK502189D0 DK502189D0 (da) 1989-10-10
DK502189A true DK502189A (da) 1989-10-12
DK174854B1 DK174854B1 (da) 2003-12-22

Family

ID=26293475

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198905021A DK174854B1 (da) 1988-02-12 1989-10-10 Antistoffer og fragmenter af antistoffer, præparater omfattende disse, anvendelse af disse til fremstilling af lægemidler samt cellelinier, der udtrykker disse

Country Status (13)

Country Link
EP (1) EP0328404B1 (da)
JP (2) JP3121823B2 (da)
AT (1) ATE95068T1 (da)
AU (1) AU618989B2 (da)
CA (1) CA1339198C (da)
DE (2) DE10199051I2 (da)
DK (1) DK174854B1 (da)
ES (1) ES2059719T3 (da)
GB (1) GB2216126B (da)
LU (1) LU90842I2 (da)
NL (1) NL300067I1 (da)
NZ (1) NZ227968A (da)
WO (1) WO1989007452A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2066720A1 (en) * 1989-09-19 1991-03-20 David M. Knight Method for improving human monoclonal antibody production
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9108056D0 (en) * 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
IL103418A (en) * 1991-10-15 1997-11-20 Wellcome Found Therapeutic agent for the t-cell mediated inflammation of the joints and its production
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
DK0671471T3 (da) * 1992-11-28 1999-10-18 Chemo Sero Therapeut Res Inst Fremgangsmåde til fremstilling af fremmed protein
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
CA2257357C (en) 1996-06-07 2010-04-13 Neorx Corporation Humanized antibodies with modified glycosylation
WO2003009740A2 (en) 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
EP1618891A1 (en) * 2003-03-31 2006-01-25 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
CA2565259A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
EP2791170A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
WO2018174274A1 (ja) 2017-03-24 2018-09-27 全薬工業株式会社 抗ＩｇＭ／Ｂ細胞表面抗原二重特異性抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product

Also Published As

Publication number Publication date
GB8902978D0 (en) 1989-03-30
CA1339198C (en) 1997-08-05
AU618989B2 (en) 1992-01-16
GB2216126A (en) 1989-10-04
JP3121823B2 (ja) 2001-01-09
EP0328404B1 (en) 1993-09-29
ES2059719T3 (es) 1994-11-16
DE10199051I1 (de) 2002-01-10
EP0328404A1 (en) 1989-08-16
LU90842I2 (fr) 2001-11-26
DK174854B1 (da) 2003-12-22
AU3062689A (en) 1989-09-06
JPH02503514A (ja) 1990-10-25
JPH11228600A (ja) 1999-08-24
ATE95068T1 (de) 1993-10-15
NZ227968A (en) 1992-01-29
DE68909441D1 (de) 1993-11-04
WO1989007452A1 (en) 1989-08-24
GB2216126B (en) 1992-06-03
DE68909441T2 (de) 1994-02-10
DK502189D0 (da) 1989-10-10
NL300067I1 (nl) 2001-12-01
DE10199051I2 (de) 2005-05-04

Similar Documents

Publication Publication Date Title
DK502189A (da) Forbedringer ved eller vedroerende antistoffer
ES2097808T3 (es) Anticuerpos de marco conservado mutado y su preparacion.
ES2137354T3 (es) Moleculas de anticuerpo anti-vla4 recombinante.
DE3854194D1 (de) Monoklonale antikörper gegen glykosyliertes albumin, hybride zellinien, die diese antikörper produzieren, sowie deren verwendung.
DE69126664D1 (de) Bestimmung von analyten in biologischen flüssigkeiten in gegenwart von störenden substanzen
PT699755E (pt) Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
DE68918497D1 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
PT649537E (pt) Imunoanalises para anticorpos anti-vhc utilizando antigenios com epitopos conformacionais
DE68903576D1 (de) Signalpeptide, die in hefe wirksam sind und ihre verwendung zur sekretorischen expression von heterologen proteinen.
ATE152244T1 (de) Verfahren zur herstellung von imunodiagnose- mitteln
CA2019671A1 (en) Oxidative denaturation of protein analytes
DE59105530D1 (de) Optisch-elektrisches messverfahren zur bestimmung von querschnittsabmessungen insbesondere strangartiger gegenstände mit bezug auf mindestens eine an den querschnittsumfang gelegte, diesen in mindestens zwei punkten berührende gerade und einrichtung zur durchführung des verfahrens.
ID25978A (id) Antibodi anti-fas
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
ID20117A (id) Antibodi anti-fas
FI922666A0 (fi) Diagnostiskt foerfarande.
DE3888887D1 (de) Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
DE69026875D1 (de) Immunobestimmung von menschlichem osteocalcin, reagenz und satz dafür
DE59208543D1 (de) Künstliche Standard- und Kontrollseren zur Verwendung in Verfahren zur Bestimmung von Antikörpern
DE69110067D1 (de) Monoklonale Antikörper gegen nicht-A 1C glykosyliertes Hämoglobin.
ATE148163T1 (de) Monoklonale antikörper gegen leptosphaeria
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
SE8705137D0 (sv) Diagnostic method for primary biliary cirrhosis and antibodies suitable to be used in certain versions of the method
DE69124294D1 (de) Monoklonale Antikörper gegen Mycosphaerella-Arten

Legal Events

Date Code Title Description
PUP Patent expired